About the Editors
The Editor-in-Chief of npj Breast Cancer is Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs at Memorial Sloan Kettering Cancer Center and Medical Director, Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology. The Founding Editor of the journal is Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service at Memorial Sloan Kettering Cancer Center. Both editors have served as President of the American Society of Clinical Oncology (ASCO) with Dr. Norton as President from 2001-2002 and Dr. Hudis as immediate past President (2013-2014).
Founding Editor and Editor-in-Chief
Larry Norton, MD, Deputy Physician-in-Chief, Breast Cancer Programs, Memorial Sloan Kettering Cancer Center; Medical Director, Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology, NY, New York, USA
Dr. Larry Norton is a board-certified medical oncologist with broad interests in cancer prevention, diagnosis, and treatment. He is currently the principal investigator of a program project grant from the National Cancer Institute (NCI), and on a national level, was formerly the Chair of the Breast Committee of the NCI’s Cancer and Leukemia Group B. He also served as President of the American Society of Clinical Oncology (ASCO) from 2001-2002, and was appointed by President Clinton to serve on the National Cancer Advisory Board. He has also received ASCO’s highest honor, the David A. Karnofsky AwardHis research concerns the basic biology of cancer; the mathematics of tumor causation and growth; and the development of approaches to better diagnosis, prevention, and drug treatment of the disease. He is involved in many areas of research including identifying the genes that predispose people to cancer or that cause cancer, developing new drugs, monoclonal antibodies that target growth factor receptors, and vaccines. A major milestone in his research career was the development of an approach to therapy called “dose density,” or “sequential dose density.” This is a new and more effective way of using anticancer drugs, based on a mathematical model he developed with his colleagues, which maximizes the killing of cancer cells while minimizing toxicity.
Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, NY, New York, USA
Dr. Clifford A. Hudis is a medical oncologist with research interests in all areas of care related to breast cancer. His clinical practice is devoted solely to the treatment of patients with breast cancer; his research is focused on prevention of the disease, prevention of recurrence after surgery, and treatment of recurrences. Working with a broad team of experts at Memorial Sloan Kettering and throughout the world, Hudis is involved in clinical and translational studies that aim to develop better hormone therapies, improved chemotherapy drugs, more-effective and less toxic methods of drug delivery, and newer highly specific agents. A particular research focus of his team at Memorial Sloan Kettering and collaborators at Weill Cornell Medical College is the interplay between inflammation, obesity, and breast cancer, and they are now actively translating their findings into clinically relevant trials with the potential to reduce the global burden of breast and other cancers. All of the clinical research he is involved with is conducted both at Memorial Sloan Kettering, through the Breast Cancer Disease Management Team and the Breast Cancer Medicine Service, and nationally through several collaborative groups including the Alliance for Clinical Trials in Oncology, where Hudis is Co-Chair of the Breast Cancer Committee, and the Translational Breast Cancer Research Consortium, where he serves on the Steering Committee. In addition, in June 2013 Hudis began a one-year term as President of the American Society of Clinical Oncology (ASCO).
Kathy S. Albain, MD, FACP, Professor of Medicine, Director Breast Clinical Research Program, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois, USA
Dr. Albain devotes her clinical practice to patients with breast and lung cancer at Loyola’s Cardinal Bernardin Cancer Center. She is Co-leader of the Breast Cancer Program (with Clodia Osipo, PhD), Director of the Breast Clinical Research Program, Co-director of the multidisciplinary Breast Oncology Center, and Director of the Thoracic Oncology Program. She is also a Fellow of the American College of Physicians. Dr. Albain is involved in national research and advisory activities pertaining to breast and lung cancers as well as cancer survivorship and special populations research. She chaired the Committee on Special Populations for SWOG from its conception, and they conducted novel research that addressed gender differences in cancer, survivorship issues, and outcome and treatment of special populations. Dr. Albain is a member of the SWOG working groups for breast and lung cancer, the International Early Breast Cancer Trialists’ Collaborative Group and Steering Committee. She was a charter member of the NIH Committee on Research on Women’s Health and completed a term on the FDA Oncologic Drugs Advisory Committee (ODAC). She has over 170 publications in peer reviewed journals.
Debra L. Barton, PhD, Professor of Nursing, University of Michigan, Ann Arbor, Michigan, USA
Dr. Barton’s area of interest and current research focus on improving the quality of life of female cancer survivors, specifically tied to cancer related fatigue, sexual health, menopausal symptoms, complementary therapy, and clinical trials. She has published over 100 research articles, and the Work from Dr. Barton and others has confirmed that the severity of vaginal symptoms, fatigue, body image, and partner issues predicts overall sexual health. Dr. Barton’s program of research has grown out of involvement and subsequently leadership in the Cancer Clinical Trials Network (CCTN) over the past 11 years. Dr. Barton has developed and/or completed, as the Principal Investigator or co-PI, 15 large Phase III randomized clinical trials in oncology symptom management, and 7 Phase II trials, funded either through the Komen Foundation or a federal R 21 grant. She is a Fellow in the American Academy of Nursing, alternate member of the Alliance to the National Cancer Institute Symptom Management/Quality of Life steering committee, and has served as a member of review committees for the National Institute of Health (NIH).
Lisa A. Carey, MD, Distinguished Professorship for Breast Cancer Research, UNC Chapel Hill, NC, USA
Dr. Carey is board-certified in both Internal Medicine and Medical Oncology. Her current research seeks to understand the impact of biology of breast cancer subtypes on response to treatment, and analyses of primary and metastatic tumors to understand why some breast cancers spread to other parts of the body and others don’t. She is the Medical Director of the UNC Breast Center, Chief of Hematology/Oncology, and Physician-in-Chief of the N.C. Cancer Hospital. Dr. Carey has worked extensively with scientists across Lineberger Comprehensive Cancer Center and the UNC Gillings Global School of Public Health to better understand and characterize the molecular subtypes of breast cancer so that we may develop better prevention and treatment strategies.In 2008, Dr. Carey was inducted into the Johns Hopkins Society of Scholars, was honored to serve as UNC's commencement speaker in 2009, received the NCI Director's Service Award in 2011, and was selected to the "Dialogues in Medicine" panel in honor of the New England Journal of Medicine 200th anniversary.
Angelo Di Leo, MD, PhD, Head of Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
Since 2003, Dr. Di Leo has served as Head of the Sandro Pitigliani Medical Oncology Dept. at the Hospital of Prato, Instituto Toscano. He is a member of the Early Breast Cancer Trialists’ Cooperative Group steering committee and of the Scientific Advisory Council of the Susan G Komen for the Cure®. He also serves as member of the Breast International Group Executive Board. Currently, Dr. Di Leo and colleagues are studying breast cancers that express estrogen receptors (ER) and HER2, referred to as ER-positive and HER2-positive, respectively. These breast cancers are treated with targeted therapies usually in combination with chemotherapy. His team will work to identify which patients could safely avoid chemotherapy, and instead receive a CDK4/6 inhibitor with their targeted therapy. CDK4/6 inhibitors are a new class of targeted drugs that have been FDA-approved for patients with advanced ER-positive breast cancer. Dr. Di Leo will use a tumor gene signature called “RBsig" to predict response to CDK4/6 inhibitors. Cancers with low levels of RBsig are less likely to respond to chemotherapy, and may respond better to anti-CDK4/6 therapy.
Jorge S. Reis-Filho, MD, PhD, Director of Experimental Pathology, Memorial Sloan Kettering Cancer Center, NY, New York, USA
Dr. Reis-Filho an affiliate member of the Human Oncology and Pathogenesis Program and the Computational Biology Center. Dr. Reis-Filho's research program focuses on the development of an integrated morphological and molecular classification for breast cancers by focusing on special histological types and the identification of novel therapeutic targets for specific subgroups of breast cancer patients, through an integrative analysis of data derived from pathology, massively parallel sequencing and functional genomics. His project has the potential to molecularly classify rare breast cancers and identify new molecular targets to tailor the treatment of breast cancer patients.He has received numerous awards, including the CL Oakley Lectureship and BACR Translational Research Award in 2007, and Ramzi Cotran Young Ivestigator Award in 2010. Dr. Reis-Filho is the youngest ever Fellow of The Royal College of Pathologists to have become a member by published works. He has alo published over 400 peer reviewed articles.
Joseph A. Sparano, MD, Professor of Medicine & Obstetrics, Gynecology and Women’s Health, Albert Einstein College of Medicine, NY, New York, USA
Dr. Sparano serves as Associate Chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, and Associate Director for Clinical Research at the Albert Einstein Cancer Center. He is also a practicing clinician who specializes in medical oncology and clinical and translational cancer research. His research has focused on developmental therapeutic approaches for breast cancer, lymphoma, and HIV-associated cancers, and therapeutic application of molecular profiling in cancer. Dr. Sparano serves as Vice Chair of the ECOG-ACRIN Research Group and Vice Chair of the AIDS Malignancy Consortium. He is former director of the Hematology-Oncology Fellowship Program at Einstein/Montefiore, co-directs the ECOG-ACRIN Young Investigator Program, and is a faculty member of the Calabresi K12 Oncology Training Program. He is co-principal investigator of the Montefiore-Einstein Minority/Underserved National Community Oncology Research Program (NCORP) grant. He has received funding from the Breast Cancer Research Foundation that is supporting the creation of a biospecimen bank designed to identify determinants of late relapse.
Zoltan Szallasi, MD, Assistant Professor of Pediatrics, Harvard Medical School, Boston, MA, USA
Dr. Szallasi serves as a Senior Research Scientist in the Informatics Program at Boston Children’s Hopstial. He received his MD from the University of Medicine in Debrecen. His postdoctoral research was in the field of molecular pharmacology of cancer at the National Cancer Institute. He has published over 60 peer reviewed articles, mainly on the molecular pharmacology and high throughput analysis of cancer. Dr. Szallasi current research focus is: How is the robust phenotype of a given cancer type coded in gene expression networks? The success of genome scale analysis of breast cancer may in fact depend on the effective combination of developing experimental models yielding robust information about human tumors and their statistically sound exploitation. Dr. Szallasi's group is working on such "dual" approaches to answer whether one can identify which patient will respond to a given chemotherapeutic agent or whether there exist different subtypes of genomic instability in breast cancer with prognostic and therapeutic relevance.